Disease · EFO_0010682
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tacrolimus vs Everolimus (RAD001): serious adverse events | 28 of 94 | 42 of 90 | 184 | NCT01625377 | Trial comparisons |
| With Intraoperative Steroids vs Without Intraoperative Steroids: Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months | 20 of 39 | 26 of 38 | 77 | NCT00149890 | Trial comparisons |
| With Intraoperative Steroids vs Without Intraoperative Steroids: serious adverse events | 18 of 39 | 23 of 38 | 77 | NCT00149890 | Trial comparisons |
| Myfortic Group vs CellCept Group: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Drug Discontinuation Due to Side Effects | 1 of 14 | 2 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Number of Participants With Bone Marrow Suppression | 0 of 14 | 0 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Number of Participants With Neurotoxicity | 0 of 14 | 0 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Incidence of Biopsy-proven Acute Cellular Rejection During the Study Period | 2 of 14 | 1 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Incidence of Cytomegalovirus Infection or Disease During the Study Period | 0 of 14 | 0 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Incidence of Graft Loss or Death During the Study Period | 0 of 14 | 0 of 15 | 29 | NCT00336817 | Trial comparisons |
| Myfortic Group vs CellCept Group: Number of Participants With Clinically Significant Decrease in Serum Creatinine From Baseline Through Week 12 | 0 of 14 | 0 of 15 | 29 | NCT00336817 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010682/comparisons